Crossmark

Commentary on: The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience

Published Online: 2024-08-20

Authors

Rutsch, Frank https://orcid.org/0000-0003-2161-9825
Salusky, Isidro B.

Ferreira, Carlos R.
Funding

Funding for this research was provided by:

Universitätsklinikum Münster
License Information

Text and Data Mining valid from 2024-08-20

Version of Record valid from 2024-08-20
More Information

Article History

Received: 29 February 2024

Accepted: 10 July 2024

First Online: 20 August 2024

Declarations

:

: F.R. has received grant support and consultancy fees from Inozyme Pharma.

Document is current